AKAN vs MNMD vs TLRY vs CGC vs CRON

For growth investors, Cronos Group Inc.

(CRON) is the stronger pick with 64. 4% revenue growth year-over-year, versus -61. 3% for Akanda Corp. (AKAN). Analysts rate Mind Medicine (MindMed) Inc. (MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Mind Medicine (MindMed) Inc.

(MNMD) delivered a total return of -55. 1%, compared to -100. 0% for Akanda Corp. (AKAN). Over 10 years, the gap is even starker: CRON returned +1439% versus AKAN's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cronos Group Inc.

(CRON) is the lower-risk stock at 0. 96β versus Tilray Brands, Inc. 's 2. 04β — meaning TLRY is approximately 113% more volatile than CRON relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cronos Group Inc.

(CRON) is pulling ahead at 64. 4% versus -61. 3% for Akanda Corp. (AKAN). On earnings-per-share growth, the picture is similar: Akanda Corp. grew EPS 100. 0% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Over a 3-year CAGR, AKAN leads at 172. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Mind Medicine (MindMed) Inc.

(MNMD) is the more profitable company, earning 0. 0% net margin versus -489. 6% for Akanda Corp. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNMD leads at 0. 0% versus -523. 8% for AKAN. At the gross margin level — before operating expenses — CRON leads at 32. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CGC: 1203.

6% to $14. 47.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cronos Group Inc.

(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 96), +1439% 10Y return). Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1439%, TLRY: -75. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AKAN is a small-cap quality compounder stock; MNMD is a small-cap quality compounder stock; TLRY is a small-cap quality compounder stock; CGC is a small-cap quality compounder stock; CRON is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.